An example is the use of nivolumab combined with andecaliximab (GS-5745) (204, 205), an inhibitory mAb of matrix metalloproteinase 9 (MMP-9) in recurrent gastric or gastroesophageal junction adenocarcinomas (NCT02864381). The gene discussed is MMP9; the disease is gastroesophageal junction adenocarcinoma.